ResultsIn the full population (n ϭ 314), seated trough mean Ϯ SE BP reductions (mmHg) with T80/A5 vs A5 from baseline to Week 8 were -16.2 Ϯ 1.3 vs -11.7 Ϯ 1.3 for SBP (p Ͻ 0.001) and -12.4 Ϯ 0.95 vs -10.2 Ϯ 0.93 for DBP (p ϭ 0.007). T80/A5 provided DBP goal attainment ( Ͻ 140/90 mmHg) in 64.5% vs 45.3% with A5 alone (p ϭ 0.007) and DBP response rate ( Ͻ 90mmHg or Ն 10mmHg reduction) was 80.0% vs 63.5% (p ϭ 0.0017). The incidence of related AEs (including peripheral edema) was 1.9% with T80/A5 and 2.4% with A5. ConclusionsIn Asian patients T80/A5 SPC provided superior BP reductions and goal rate achivement vs A5 monotherapy after 8 weeks of treatment, T80/A5 was well-tolerated and had a safety profi le comparable to A5 monotherapy.Background Urinary albumin excretion (UAE) is a surrogate marker of cardiovascular events in hypertensive patients. Recently, Morning Hypertension and Angiotensin Receptor Blocker/ Hydrochlorothiazide Combination Therapy (MAPPY) study has shown that losartan/ hydrochlorothiazide combination is superior to high-dose losartan